MMED Stock Forecast & Price Target

Minimed Group is well positioned for a positive re-rating because it is emerging from Medtronic’s shadow with a cleaner strategic focus, a stronger leadership team under Que Dallara, and a unique full-stack diabetes platform spanning pumps, CGMs, smart pens, and pharmacy access. Its turnaround is supported by accelerating product cycles, including Flex launched in Jun. ’26, Fit in mid-CY27, and a fully closed-loop system in 2HCY27, alongside improving physician sentiment, higher CGM attachment, and a path to roughly 9-10%+ revenue growth. The company’s fundamentals also look attractive given its recurring consumables model, expected EBITDA expansion above $800M by FY29, and the potential for margin and multiple upside as split-off volatility fades.

Minimed Group is viewed negatively because its growth depends on a narrow set of pump and CGM catalysts while facing intensifying competition, with tubeless rivals already gaining share and durable pumps remaining the slower-growing, margin-disadvantaged segment. The company also faces execution risk around pharmacy-channel economics, the summer 2027 FIT patch pump launch, and dependence on Abbott as the exclusive third-party CGM supplier, any of which could slow new patient starts or force existing patients to switch. Financially, the post-spin structure still leaves MMED with about 90% ownership by MDT, ongoing stand-up costs, royalty payments, and a potential ~$162M non-cash charge tied to Blackstone, all of which can weigh on margin ramp and keep the “management overhang” in place.